ResMed Inc. 10-Q Summary: Quarter Ended September 30, 2001
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for ResMed Inc., a Delaware corporation specializing in devices for the evaluation and treatment of sleep-disordered breathing. The report covers the three-month period ended September 30, 2001. The company's principal manufacturing operations are located in Australia, with major distribution and sales sites in the United States, Europe, and Singapore.
Key Financial Metrics
| Metric | Q3 2001 | Q3 2000 |
|---|---|---|
| Net Revenue | $46.1 million | $31.1 million |
| Gross Profit | $30.8 million | $21.1 million |
| Gross Margin | 67% | 68% |
| Operating Income | $13.2 million | $9.1 million |
| Net Income | $8.5 million | $6.6 million |
| Diluted EPS | $0.25 | $0.20 |
| Cash from Operations | $11.2 million | $6.3 million |
| Cash & Equivalents (End of Period) | $60.4 million | $13.6 million |
| Marketable Securities | $83.1 million | N/A |
| Convertible Subordinated Notes | $180.0 million | N/A |
| Working Capital | $186.7 million | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 48% year-over-year, driven by higher unit sales of flow generators and accessories and the acquisition of MAP Medizin-Technologie GmbH (MAP), which contributed $6.2 million in revenue.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 49% to $14.3 million, and R&D expenses increased 41% to $3.4 million, largely due to personnel expansion and MAP integration.
- Debt Issuance: In June 2001, the company issued $180 million in 4% convertible subordinated notes (including $30 million in over-allotments), resulting in increased interest expense.
- Tax Rate: The effective income tax rate declined to 32.1% from 34.1%, primarily due to a reduction in the Australian corporate tax rate from 34% to 30%.
- Capital Expenditures: Capex decreased significantly to $2.7 million from $19.2 million in the prior year, as the previous period included a $17.2 million purchase of the US headquarters.
Guidance, Outlook, and Risks
- Accounting Changes: The company adopted SFAS 142 (Goodwill) effective July 1, 2001. Goodwill is no longer amortized but tested for impairment annually. The company is currently assessing goodwill (carrying value $51.4 million) for impairment, with results expected by December 31, 2001.
- Expansion Plans: The company purchased a 30-acre site in Sydney, Australia, for approximately $21 million (staged over 18 months) to build a new manufacturing facility, expected to be operational in early 2003. Total project costs are estimated at $43.5 million.
- Legal Proceedings: Ongoing patent litigation against Respironics in the US District Court for the Western District of Pennsylvania. The court has granted three partial summary judgment motions for non-infringement in favor of Respironics; ResMed intends to appeal. Additionally, a trademark/patent lawsuit in Germany against Hofrichter GmbH is pending appeal.
- Market Risks: The company faces foreign currency exchange risk (hedged via options) and interest rate risk regarding its investment portfolio.
Investor Verification Checklist
- Verify the outcome of the goodwill impairment assessment under SFAS 142, expected by December 31, 2001.
- Monitor the status of the patent litigation against Respironics and the potential impact of an adverse final judgment.
- Track the progress and cost overruns of the new Sydney manufacturing facility construction.
- Review the sustainability of the 48% revenue growth rate post-acquisition of MAP.
- Assess the impact of the $180 million convertible debt on future interest expenses and liquidity.